These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21221469)

  • 1. Prevalence of carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii in high complexity hospital.
    Baumgart AM; Molinari MA; Silveira AC
    Braz J Infect Dis; 2010; 14(5):433-6. PubMed ID: 21221469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing resistance rate to carbapenem among blood culture isolates of Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa in a university-affiliated hospital in China, 2004-2011.
    Zhang X; Gu B; Mei Y; Wen Y; Xia W
    J Antibiot (Tokyo); 2015 Feb; 68(2):115-20. PubMed ID: 25182483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of ertapenem use on Pseudomonas aeruginosa and Acinetobacter baumannii imipenem susceptibility rates: collateral damage or positive effect on hospital ecology?
    Sousa D; Castelo-Corral L; Gutiérrez-Urbón JM; Molina F; López-Calviño B; Bou G; Llinares P
    J Antimicrob Chemother; 2013 Aug; 68(8):1917-25. PubMed ID: 23557925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
    Davies TA; Marie Queenan A; Morrow BJ; Shang W; Amsler K; He W; Lynch AS; Pillar C; Flamm RK
    J Antimicrob Chemother; 2011 Oct; 66(10):2298-307. PubMed ID: 21775338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro sensitivity of Acinetobacter baumannii and Pseudomonas aeruginosa to carbapenems among intensive care unit patients.
    Guzek A; Korzeniewski K; Nitsch-Osuch A; Rybicki Z; Prokop E
    Adv Exp Med Biol; 2013; 788():109-16. PubMed ID: 23835967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and 30-day all-cause mortality of carbapenem-and colistin-resistant bacteraemia caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae: Description of a decade-long trend.
    Balkhair A; Al-Muharrmi Z; Al'Adawi B; Al Busaidi I; Taher HB; Al-Siyabi T; Al Amin M; Hassan KS
    Int J Infect Dis; 2019 Aug; 85():10-15. PubMed ID: 31100418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is There a Carbapenem MIC Cutoff Value That Distinguishes Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem Non-Susceptible Pseudomonas and Acinetobacter Isolates?
    Tamma PD; Wang R; Lewis S; Opene BNA; Simner PJ
    Infect Control Hosp Epidemiol; 2017 Nov; 38(11):1378-1379. PubMed ID: 28965496
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa.
    Kuti JL; Florea NR; Nightingale CH; Nicolau DP
    Pharmacotherapy; 2004 Jan; 24(1):8-15. PubMed ID: 14740783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study.
    McCracken M; Mataseje LF; Loo V; Walkty A; Adam HJ; Hoban DJ; Zhanel GG; Mulvey MR;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):335-41. PubMed ID: 21353962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrointestinal selective capacity of doripenem, meropenem, and imipenem for carbapenem-resistant gram-negative bacilli in treated patients with pneumonia.
    Apisarnthanarak A; Kiratisin P; Apisarnthanarak P; Mundy LM
    Infect Control Hosp Epidemiol; 2011 Apr; 32(4):410-1. PubMed ID: 21460501
    [No Abstract]   [Full Text] [Related]  

  • 11. Activities of doripenem against nosocomial bacteremic drug-resistant Gram-negative bacteria in a medical center in Taiwan.
    Dong SX; Wang JT; Chang SC
    J Microbiol Immunol Infect; 2012 Dec; 45(6):459-64. PubMed ID: 23102796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.
    Villegas MV; Briceno DF; Ruiz SJ; Furtado GH; Nicolau DP
    Braz J Infect Dis; 2011; 15(5):413-9. PubMed ID: 22230846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of the distribution characteristics and drug resistance of non-fermenting bacterial infection in intensive care unit from 2009 to 2015].
    Hao D; Hu Z; Liu X; Sun T; Wang T; Tian H; Wang X
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2016 May; 28(5):439-44. PubMed ID: 29920041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of disk diffusion test for carbapenem sensitivity in Acinetobacter baumannii and Pseudomonas aeruginosa strains].
    Akan OA; Uysal S
    Mikrobiyol Bul; 2005 Jul; 39(3):273-9. PubMed ID: 16358486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Shall we report the carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii strains detected by BD Phoenix system?].
    Oğünç D; Ongüt G; Ozen NS; Baysan BO; Günseren F; Dağlar D; Demirbakan H; Gültekin M
    Mikrobiyol Bul; 2010 Apr; 44(2):197-202. PubMed ID: 20549953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences between meropenem and imipenem disk to detect carbapenemase in gram-negative bacilli using simplified carbapenem inactivation method.
    Wan D; Jing X; Zhou H; Min X; Zhang X; Wu T; Liu R; Zeng J
    J Infect Chemother; 2020 Jun; 26(6):636-639. PubMed ID: 32173284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can Plazomicin Alone or in Combination Be a Therapeutic Option against Carbapenem-Resistant Acinetobacter baumannii?
    García-Salguero C; Rodríguez-Avial I; Picazo JJ; Culebras E
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5959-66. PubMed ID: 26169398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Four years of monitoring of antibiotic sensitivity rates of Pseudomonas aeruginosa and Acinetobacter baumannii strains isolated from patients in intensive care unit and inpatient clinics].
    Alişkan H; Colakoğlu S; Turunç T; Demiroğlu YZ; Erdoğan F; Akin S; Arslan H
    Mikrobiyol Bul; 2008 Apr; 42(2):321-9. PubMed ID: 18697430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiological, Physiological, and Molecular Characteristics of a Brazilian Collection of Carbapenem-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa.
    Dias VC; Resende JA; Bastos AN; De Andrade Bastos LQ; De Andrade Bastos VQ; Bastos RV; Diniz CG; Da Silva VL
    Microb Drug Resist; 2017 Oct; 23(7):852-863. PubMed ID: 28437232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doripenem vs meropenem against Pseudomonas and Acinetobacter.
    Goyal K; Gautam V; Ray P
    Indian J Med Microbiol; 2012; 30(3):350-1. PubMed ID: 22885206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.